Want to see IN:KOPRAN full AI Analyst Report?
Top Page
Kopran Limited
(KOPRAN)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹246.00
▲(61.63% Upside)
Action:Reiterated
Date:09/17/26
The score is held back primarily by weaker financial quality—especially persistently negative free cash flow and uneven profitability—despite healthy revenue growth and a manageable leverage profile. Technicals are strong with clear bullish trend signals, but momentum appears overbought, and the high P/E valuation limits upside confidence.
Positive Factors
Accelerating Revenue Growth
The acceleration in FY2026 indicates strengthening demand across Kopran’s pharmaceutical activities after modest prior-year growth. Continued top-line expansion can improve operating scale, support investment in products and capacity, and reinforce the company’s market position over the next several quarters.
Negative Factors
Persistently Negative Free Cash Flow
Repeatedly negative free cash flow indicates that investment requirements or working-capital needs are absorbing operating cash generation. If sustained, this reduces Kopran’s ability to self-fund expansion, dividends, or debt reduction and may increase reliance on external funding for ongoing growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
The acceleration in FY2026 indicates strengthening demand across Kopran’s pharmaceutical activities after modest prior-year growth. Continued top-line expansion can improve operating scale, support investment in products and capacity, and reinforce the company’s market position over the next several quarters.
Read all positive factors
Kopran Limited (KOPRAN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹11.56B
Dividend Yield1.25%
Average Volume (3M)37.83K
Price to Earnings (P/E)46.2
Beta (1Y)1.40
Revenue Growth11.96%
EPS Growth-28.48%
CountryIN
Employees1,156
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)5.17
Shares Outstanding48,326,103
10 Day Avg. Volume21,098
30 Day Avg. Volume37,828
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kopran Limited Business Overview & Revenue Model
Company Description
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes...
How the Company Makes Money
Kopran Limited primarily makes money by selling (1) finished pharmaceutical formulations (branded and/or generic medicines in dosage forms such as tablets, capsules, syrups, etc.) and (2) active pharmaceutical ingredients (APIs) supplied to other ...
Kopran Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.00B | 6.81B | 6.30B | 6.15B | 5.48B | 4.74B |
| Gross Profit | 1.89B | 1.60B | 2.25B | 2.09B | 1.86B | 1.90B |
| EBITDA | 614.17M | 623.00M | 729.00M | 868.18M | 548.62M | 980.11M |
| Net Income | 249.83M | 257.31M | 385.52M | 509.56M | 272.33M | 610.31M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.08B | 8.44B | 7.43B | 6.50B | 6.11B |
| Cash, Cash Equivalents and Short-Term Investments | 6.82M | 72.22M | 258.64M | 80.91M | 73.97M | 58.68M |
| Total Debt | 0.00 | 1.53B | 1.48B | 992.28M | 752.38M | 745.49M |
| Total Liabilities | -5.30B | 3.78B | 3.26B | 2.52B | 2.10B | 1.85B |
| Stockholders Equity | 5.30B | 5.30B | 5.18B | 4.91B | 4.39B | 4.26B |
Cash Flow | ||||||
| Free Cash Flow | 234.30M | -105.46M | -134.46M | -133.56M | -270.22M | -757.47M |
| Operating Cash Flow | 553.87M | 565.79M | 419.42M | 432.58M | 340.23M | -334.75M |
| Investing Cash Flow | -335.65M | -648.97M | -564.28M | -435.52M | -126.50M | -844.15M |
| Financing Cash Flow | -107.78M | -104.72M | 258.68M | 9.88M | -198.44M | 1.23B |
Kopran Limited Technical Analysis
Negative
152.20
Price Trends
248.71
Negative
218.74
Positive
180.84
Positive
Market Momentum
-1.94
Positive
40.55
Neutral
21.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Negative. The current price of 152.2 is below the 20-day moving average (MA) of 262.53, below the 50-day MA of 248.71, and below the 200-day MA of 180.84, indicating a neutral trend. The MACD of -1.94 indicates Positive momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KOPRAN.
Kopran Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹1.11T | 38.44 | ― | 2.10% | -0.74% | -46.77% | |
70 Outperform | ₹138.96B | 26.84 | ― | 0.29% | 19.59% | 47.58% | |
70 Outperform | ₹73.80B | 20.24 | ― | 3.84% | -5.74% | 2.30% | |
63 Neutral | ₹47.93B | 45.49 | ― | 0.08% | 10.25% | 33.78% | |
57 Neutral | ₹15.76B | 27.28 | ― | 0.07% | 40.45% | 174.03% | |
56 Neutral | ₹11.56B | 46.24 | ― | 1.25% | 11.96% | -28.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:KOPRAN
Kopran Limited
239.30
76.36
46.87%
IN:CIPLA
Cipla Ltd
1,380.00
-107.68
-7.24%
IN:MARKSANS
Marksans Pharma Limited
306.65
125.20
69.00%
IN:NGLFINE
NGL Fine-Chem Ltd.
2,551.05
1,048.85
69.82%
IN:SANOFI
Sanofi India Limited
3,204.40
-1,437.14
-30.96%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
511.75
225.80
78.96%
Kopran Limited Corporate Events
Kopran Confirms SEBI Demat Compliance for September Quarter
Oct 12, 2026
Kopran Limited has confirmed compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The company stated that this certification is based on information provided by it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.